Tower Research Capital LLC TRC Has $481,000 Stock Holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

Tower Research Capital LLC TRC boosted its holdings in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 958.2% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 45,576 shares of the company's stock after acquiring an additional 41,269 shares during the quarter. Tower Research Capital LLC TRC's holdings in ARS Pharmaceuticals were worth $481,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Allspring Global Investments Holdings LLC boosted its holdings in shares of ARS Pharmaceuticals by 93.1% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 344,171 shares of the company's stock worth $3,631,000 after purchasing an additional 165,950 shares during the period. Peregrine Capital Management LLC purchased a new position in shares of ARS Pharmaceuticals during the 4th quarter valued at $4,469,000. Vanguard Group Inc. raised its holdings in shares of ARS Pharmaceuticals by 3.5% during the fourth quarter. Vanguard Group Inc. now owns 3,464,952 shares of the company's stock worth $36,555,000 after acquiring an additional 115,656 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in ARS Pharmaceuticals by 0.8% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 427,477 shares of the company's stock valued at $4,510,000 after purchasing an additional 3,530 shares in the last quarter. Finally, Barclays PLC increased its position in ARS Pharmaceuticals by 189.7% in the 3rd quarter. Barclays PLC now owns 111,666 shares of the company's stock worth $1,618,000 after purchasing an additional 73,127 shares during the last quarter. Hedge funds and other institutional investors own 68.16% of the company's stock.

Wall Street Analyst Weigh In

SPRY has been the topic of a number of research reports. Leerink Partners increased their price objective on ARS Pharmaceuticals from $26.00 to $27.00 and gave the stock an "outperform" rating in a report on Monday, January 13th. William Blair restated an "outperform" rating on shares of ARS Pharmaceuticals in a report on Monday, March 3rd. Scotiabank started coverage on shares of ARS Pharmaceuticals in a report on Friday, March 7th. They issued a "sector outperform" rating and a $30.00 price objective for the company. Raymond James raised their target price on ARS Pharmaceuticals from $26.00 to $28.00 and gave the company a "strong-buy" rating in a report on Tuesday, January 14th. Finally, Oppenheimer assumed coverage on ARS Pharmaceuticals in a research note on Monday, February 10th. They set an "outperform" rating and a $40.00 price target for the company. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, ARS Pharmaceuticals currently has a consensus rating of "Buy" and an average target price of $31.00.

ARS Pharmaceuticals Stock Down 1.5 %

NASDAQ:SPRY traded down $0.22 during trading hours on Monday, reaching $14.25. The company had a trading volume of 99,411 shares, compared to its average volume of 1,176,429. The stock has a 50-day moving average of $12.81 and a two-hundred day moving average of $13.02. ARS Pharmaceuticals, Inc. has a one year low of $7.55 and a one year high of $18.51. The firm has a market capitalization of $1.40 billion, a PE ratio of -27.67 and a beta of 0.86.

ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) last posted its earnings results on Thursday, March 20th. The company reported $0.52 earnings per share for the quarter, topping the consensus estimate of ($0.04) by $0.56. The firm had revenue of $86.58 million during the quarter, compared to the consensus estimate of $15.46 million. As a group, sell-side analysts expect that ARS Pharmaceuticals, Inc. will post -0.55 earnings per share for the current year.

Insider Buying and Selling at ARS Pharmaceuticals

In other ARS Pharmaceuticals news, Director Laura Shawver sold 49,600 shares of the company's stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $11.21, for a total transaction of $556,016.00. Following the transaction, the director now owns 210,346 shares of the company's stock, valued at approximately $2,357,978.66. This represents a 19.08 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Eric Karas sold 10,000 shares of the firm's stock in a transaction dated Thursday, March 20th. The shares were sold at an average price of $14.00, for a total value of $140,000.00. Following the completion of the transaction, the insider now owns 7,696 shares in the company, valued at approximately $107,744. This represents a 56.51 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 109,602 shares of company stock worth $1,311,041. 40.10% of the stock is currently owned by insiders.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.